Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ad26 Mos HIV trivalent vaccine - Janssen Vaccines and Prevention B.V

Next Previous
Drug Profile

Ad26 Mos HIV trivalent vaccine - Janssen Vaccines and Prevention B.V

Alternative Names: Ad26 Mos HIV; Ad26 Mos HIV + clade C gp140; Ad26 mosaic vector + gp140; Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Ad26.Mos.HIV + gp140; Adenovirus-serotype-26-Mosaic-HIV-vaccine; Adenovirus-serotype-26-Mosaic-HIV-vaccine + Clade C glycoprotein 140; HIV Px Vaccine; JNJ-9220

Latest Information Update: 06 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crucell Holland
  • Developer Beth Israel Deaconess Medical Center; International AIDS Vaccine Initiative; Janssen Vaccines and Prevention B.V; Johnson & Johnson; U.S. Military HIV Research Program
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 14 Jan 2025 Discontinued - Phase-I/II for HIV infections (Combination therapy, Treatment-experienced) in Thailand (IM)
  • 14 Jan 2025 Discontinued - Phase-I/II for HIV infections (Prevention) in Rwanda (IM)
  • 14 Jan 2025 Discontinued - Phase-I/II for HIV infections (Prevention) in South Africa (IM)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top